Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070367 | 1.00 | ESR1 (1.00) | ESR1ESR2PGRCYP19A1 | |
| SCHEMBL21512474 | 1.00 | ESR1 (1.00) | ESR1ESR2PGRCYP19A1 | |
| SCHEMBL5070365 | 1.00 | ESR1 (1.00) | ESR1ESR2PGRCYP19A1 | |
| SCHEMBL28483063 | 1.00 | ESR1 (1.00) | ESR1ESR2PGRCYP19A1 | |
| SCHEMBL3809279 | 0.96 | ESR1 (0.92) | ESR1ESR2PGR | |
| SCHEMBL3809277 | 0.96 | ESR1 (0.92) | ESR1ESR2PGR | |
| SCHEMBL667262 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407673 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL407674 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR | |
| SCHEMBL6903749 | 0.94 | ESR1 (1.00) | ESR1ESR2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220955-A2 | COMBINING INDUCTION OF FERROPTOSIS WITH TARGETED AGENTS FOR CANCER THERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-10-24 | — | — | WO | claimed |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. | 2023-10-26 | — | — | US | claimed |
| WO-2022026901-A2 | NK ANTAGONISTS FOR CONTRACEPTION | ACER THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-4739801-A1 | CLASSIFICATION, TREATMENT, AND TREATMENT RESPONSE OF CANCER PATIENTS | OncoGenomX (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12441744-B2 | 2,6,9-trisubstituted purines | ASTRAZENECA AB | 2025-10-14 | — | — | US | disclosed |
| WO-2025202991-A1 | CRYSTALLINE FORM OF (S)-N-ETHYL-3-((9-ETHYL-2-(((2R,3S)-2-HYDROXYPENTAN-3-YL)AMINO)-9H-PURIN-6-YL)AMINO)-PYRROLIDINE-1-SULFONAMIDE | ASTRAZENECA AB (SE) | 2025-10-02 | — | — | WO | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4593824-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| WO-2014008159-A1 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS FOR TREATMENT OF TAMOXIFEN RESISTANT TUMORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-01-09 | — | — | WO | disclosed |
| US-7442833-B2 | Triphenylethylene compounds as selective estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1019057-B1 | A METHOD OF PREVENTING OR TREATING ESTROGEN-DEPENDENT DISEASES AND DISORDERS | UNIV DUKE (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1692127-B1 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7307102-B2 | Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity | DUKE UNIVERSITY (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307102-B2 | Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity | DUKE UNIVERSITY (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070111971-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2007-05-17 | — | — | US | disclosed |
| EP-1692127-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005033056-A2 | TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | ESR1 31/4885ESR2 14/4885PGR 28/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | ESR1 99/4885ESR2 55/4885PGR 81/4885 |
| US-12441744-B2 | 2,6,9-trisubstituted purines | CDK2, CDK1, CCNT2 | ESR1 1433/4885ESR2 2143/4885PGR 678/4885 |
| US-20250197425-A1 | 2,6,9-TRISUBSTITUTED PURINES | CDK2, CDK1, CCNT2 | ESR1 1433/4885ESR2 2143/4885PGR 678/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | ESR1 77/4885ESR2 38/4885PGR 58/4885 |
| US-20230338355-A1 | NK ANTAGONISTS FOR CONTRACEPTION | KLKB1, KLK3, SHBG | ESR1 1083/4885ESR2 677/4885PGR 83/4885 |
| US-20070111971-A1 | Novel compounds | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885PGR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.